Harbour Investments Inc. Makes New Investment in ADMA Biologics Inc $ADMA

Key Points

• Harbour Investments Inc. has acquired 35,575 shares of ADMA Biologics Inc, valued at approximately $648,000, marking a significant new investment in the biotechnology firm.
• ADMA Biologics has received positive ratings from analysts, with a consensus rating of "Buy" and a target price of $27.67.
• The company reported earnings of $0.15 per share for the last quarter, exceeding estimates and showing a year-over-year revenue increase of 13.8%.

Harbour Investments Inc. bought a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 35,575 shares of the biotechnology company's stock, valued at approximately $648,000.

A number of other hedge funds also recently bought and sold shares of ADMA. Skandinaviska Enskilda Banken AB publ purchased a new stake in ADMA Biologics during the first quarter worth $35,000. SVB Wealth LLC purchased a new stake in ADMA Biologics during the first quarter worth $35,000. Toth Financial Advisory Corp lifted its holdings in ADMA Biologics by 1,081.6% during the second quarter. Toth Financial Advisory Corp now owns 2,505 shares of the biotechnology company's stock worth $46,000 after buying an additional 2,293 shares during the period. Ameritas Advisory Services LLC purchased a new stake in ADMA Biologics during the second quarter worth $46,000. Finally, Smartleaf Asset Management LLC increased its position in shares of ADMA Biologics by 161.4% during the first quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company's stock worth $49,000 after purchasing an additional 1,493 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a "buy (b-)" rating on shares of ADMA Biologics in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the stock. Based on data from MarketBeat.com, ADMA Biologics has a consensus rating of "Buy" and a consensus price target of $27.67.

ADMA Biologics Price Performance

NASDAQ ADMA opened at $14.36 on Monday. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. The stock's fifty day moving average price is $16.00 and its 200 day moving average price is $18.36. ADMA Biologics Inc has a 1 year low of $13.50 and a 1 year high of $25.67. The company has a market cap of $3.43 billion, a price-to-earnings ratio of 16.70 and a beta of 0.47.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The firm had revenue of $121.98 million for the quarter, compared to the consensus estimate of $121.77 million. During the same period in the prior year, the firm earned $0.13 EPS. The firm's revenue was up 13.8% on a year-over-year basis. As a group, equities research analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.